MAXCYTE INC (MXCT) Earnings History & Surprises
NASDAQ:MXCT • US57777K1060
0.7824 USD
-0.05 (-6.37%)
At close: Mar 6, 2026
0.8 USD
+0.02 (+2.25%)
After Hours: 3/6/2026, 8:00:02 PM
Past quarterly earnings results for MAXCYTE INC (MXCT), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMar 24, 2026
PeriodQ4 / 2025
EPS Estimate-$0.08
Revenue Estimate9.586M
Last Reported
Release DateNov 12, 2025
PeriodQ3 / 2025
EPS Reported-$0.09
EPS Surprise 19.79%
Revenue Surprise -20.01%
Beat Rate
81%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.09 | -0.11 | 19.79% | 18.18% | 6.829M | 8.537M | -20.01% | -16.35% |
| Q2 2025 | -0.12 | -0.11 | -13.86% | -33.33% | 8.507M | 9.719M | -12.47% | -18.43% |
| Q1 2025 | -0.10 | -0.11 | 6.63% | -11.11% | 10.39M | 9.869M | 5.28% | -8.39% |
| Q4 2024 | -0.10 | -0.12 | 19.64% | -100.00% | 8.693M | 8.086M | 7.51% | -44.51% |
| Q3 2024 | -0.11 | -0.13 | 12.56% | - | 8.164M | 7.522M | 8.53% | 1.99% |
| Q2 2024 | -0.09 | -0.13 | 30.34% | 10.00% | 10.429M | 8.079M | 29.09% | 15.33% |
| Q1 2024 | -0.09 | -0.13 | 32.13% | 18.18% | 11.342M | 7.611M | 49.02% | 32.25% |
| Q4 2023 | -0.05 | -0.07 | 31.92% | - | 15.666M | 13.356M | 17.30% | 26.14% |
| Q3 2023 | -0.11 | -0.10 | -5.73% | -83.33% | 8.005M | 9.247M | -13.44% | -24.77% |
| Q2 2023 | -0.10 | -0.10 | -2.12% | -25.00% | 9.043M | 11.003M | -17.82% | -5.90% |
| Q1 2023 | -0.11 | -0.11 | 3.71% | -175.00% | 8.576M | 8.495M | 0.96% | -26.00% |
| Q4 2022 | -0.05 | -0.07 | 29.97% | - | 12.42M | 13.154M | -5.58% | 22.36% |
| Q3 2022 | -0.06 | -0.08 | 28.26% | -100.00% | 10.64M | 10.639M | 0.01% | 4.93% |
| Q2 2022 | -0.08 | -0.08 | 1.96% | -60.00% | 9.61M | 9.407M | 2.16% | 35.16% |
| Q1 2022 | -0.04 | -0.07 | 45.53% | - | 11.59M | 8.629M | 34.31% | - |
| Q4 2021 | -0.05 | -0.06 | 9.22% | 28.57% | 10.15M | 9.645M | 5.24% | -33.56% |
| Q3 2021 | -0.03 | -0.05 | 38.73% | - | 10.14M | 7.521M | 34.82% | - |
| Q2 2021 | -0.05 | -0.07 | 24.59% | - | 7.11M | 5.847M | 21.60% | -34.73% |
| Q4 2020 | -0.07 | -0.10 | 30.69% | - | 15.277M | - | - | |
| Q2 2020 | - | - | 10.892M | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
8.05%
Max EPS beat (4)
19.79%
Min EPS beat (4)
-13.86%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
-4.92%
Max Revenue beat (4)
7.51%
Min Revenue beat (4)
-20.01%
Analysis
In the last 4 quarters, MXCT has beaten EPS estimates in 3 out of 4 releases
MXCT has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, MXCT has beaten the EPS estimates by 8.0% on average.
In the last 4 quarters, MXCT reported -4.9% below the revenue estimates on average.
MAXCYTE INC / MXCT Earnings FAQ
What is the most recent earnings date for MXCT stock?
MAXCYTE INC (MXCT) last reported earnings on 11/12/2025.
Can you provide information on whether MAXCYTE INC beat earnings estimates in the last quarter?
MAXCYTE INC (MXCT) beat EPS estimates and missed revenue estimates in the most recent quarter.
How often does MAXCYTE INC (MXCT) beat earnings estimates?
In the last 4 quarters, MAXCYTE INC (MXCT) has beaten EPS estimates in 3 out of 4 releases.